


WHAT IS CLAIMED

1. A compound of Formula I



or a pharmaceutically acceptable salt thereof, wherein:

- 10 T is CH or N, provided that no more than two of T, U and V is N;
 U is CH or N;
 V is CH or N;

W is

- 15 1) a bond, or
 2) O;

Q is

- 20 1) N, or
 2) CR³;

X is

- 25 1) O, or
 2) CH₂;

Y is

- 1) O,
 2) NR⁸,
 3) S, or

4) CH₂,

provided that when Y is O, NR⁸ or S then X is not O;

Z is

- 5 1) O,
 2) S,
 3) CH₂, or
 4) NH,

provided that when Z is O, S or NH, then X is not O;

10

A is

- 1) -C(=NH)-NH,
 2) -(CH₂)_qN(R⁷)-AryC,
 3) -(CH₂)_qO-AryC,
 15 4) AryC,
 5) -(CH₂)_qN(R⁷)-HetC,
 6) -(CH₂)_qO-HetC,
 7) HetC, or
 8) C₃-C₇ cycloalkyl,

20 wherein CH₂ and C₃-C₇ cycloalkyl are unsubstituted or substituted with one to four Rⁱ;

AryC is a 5- to 6-membered monocyclic aromatic ring with 0, 1, 2, or 3 ring atoms independently selected from N, N as a quaternary salt, O and S, unsubstituted or substituted with one to four Rⁱ, wherein AryC is optionally fused to a 4- to 7- membered
 25 heterocycloalkyl ring containing one to two heteroatoms selected from O, S and -NR^g;

HetC is a 4- to 7-membered saturated or monounsaturated monocyclic ring with 1, 2, or 3 heteroatom ring atoms independently selected from N, N as a quaternary salt, O and S, unsubstituted or substituted with one to four Rⁱ;

30

L is

- 1) absent,
 2) R⁴,
 3) -NHR⁴,
 35 4) -N(R⁴)₂,
 5) -OR⁴,
 6) -(CH₂)_nR⁴,

- 7) $-\text{C}(\text{O})\text{R}^4$,
- 8) $-\text{C}(\text{NH})\text{R}^4$, or
- 9) $-\text{S}(\text{O})_m\text{R}^4$,

wherein L is unsubstituted or substituted with 1-4 substituents selected from R^e ;

5

M is

- 1) R^5 ,
- 2) $-\text{NHR}^5$,
- 3) $-\text{N}(\text{R}^5)_2$,
- 4) $-\text{OR}^5$,
- 5) $-(\text{CH}_2)_u\text{R}^5$,
- 6) $-\text{C}(\text{O})\text{R}^5$,
- 7) $-\text{C}(\text{NH})\text{R}^5$, or
- 8) $-\text{S}(\text{O})_v\text{R}^5$,

10

15 wherein M is unsubstituted or substituted with 1 - 4 substituents selected from R^6 ;

R^1 is

- 1) hydrogen,
- 2) $-\text{C}_1\text{-C}_8$ alkyl,
- 3) $-\text{C}_3\text{-C}_7$ cycloalkyl,
- 4) $-\text{C}(\text{O})\text{OR}^e$,
- 5) $-\text{C}(\text{O})\text{NR}^c\text{R}^d$,
- 6) tetrazolyl,
- 7) oxadiazolonyl,
- 8) HetA,
- 9) AryA,
- 10) $-\text{S}(\text{O})_m\text{R}^e$,
- 11) $-\text{S}(\text{O})_m\text{NR}^c\text{R}^d$, or
- 12) $-\text{P}(\text{O})(\text{R}^e)_p$,

20

25

30 wherein $-\text{C}_1\text{-C}_8$ alkyl and $-\text{C}_3\text{-C}_7$ cycloalkyl are unsubstituted or substituted with one to three R^a ;

R^2 is

- 1) hydrogen,
- 2) $-\text{C}_1\text{-C}_8$ alkyl,
- 3) $-\text{C}_3\text{-C}_7$ cycloalkyl,
- 4) $-\text{C}(\text{O})\text{OR}^e$,

35

- 5) $-\text{C}(\text{O})\text{NR}^{\text{c}}\text{R}^{\text{d}}$,
 6) tetrazolyl,
 7) oxadiazolonyl,
 8) HetA,
 9) AryA,
 10) $-\text{S}(\text{O})_{\text{m}}\text{R}^{\text{e}}$,
 11) $-\text{S}(\text{O})_{\text{m}}\text{NR}^{\text{c}}\text{R}^{\text{d}}$, or
 12) $-\text{P}(\text{O})(\text{R}^{\text{e}})_{\text{p}}$,

wherein $-\text{C}_1\text{-C}_8$ alkyl and $-\text{C}_3\text{-C}_7$ cycloalkyl are unsubstituted or substituted with one to three R^{a} ,

provided that when R^1 is $-\text{C}(\text{O})\text{OR}^{\text{e}}$, $-\text{C}(\text{O})\text{NR}^{\text{c}}\text{R}^{\text{d}}$, $-\text{S}(\text{O})_{\text{m}}\text{R}^{\text{e}}$, $-\text{S}(\text{O})_{\text{m}}\text{NR}^{\text{c}}\text{R}^{\text{d}}$, or $-\text{P}(\text{O})(\text{R}^{\text{e}})_{\text{p}}$, then R^2 is not $-\text{C}(\text{O})\text{OR}^{\text{e}}$, $-\text{C}(\text{O})\text{NR}^{\text{c}}\text{R}^{\text{d}}$, $-\text{S}(\text{O})_{\text{m}}\text{R}^{\text{e}}$, $-\text{S}(\text{O})_{\text{m}}\text{NR}^{\text{c}}\text{R}^{\text{d}}$, or $-\text{P}(\text{O})(\text{R}^{\text{e}})_{\text{p}}$;

HetA is a 4- to 7- membered saturated or monounsaturated monocyclic ring with 1, 2, or 3 heteroatom ring atoms independently selected from N, N as a quaternary salt, O and S, unsubstituted or substituted with one to four R^{c} ;

AryA is a 5- to 6-membered monocyclic aromatic ring with 0, 1, 2, or 3 ring atoms independently selected from N, N as a quaternary salt, O and S, unsubstituted or substituted with one to four R^{c} ;

R^3 is

- 1) hydrogen,
 2) $\text{C}_1\text{-C}_4$ alkyl,
 3) halogen, or
 4) $\text{C}_3\text{-C}_7$ cycloalkyl,

wherein $\text{C}_1\text{-C}_4$ alkyl and $\text{C}_3\text{-C}_7$ cycloalkyl are unsubstituted or substituted with one to three R^{a} ,

each occurrence of R^4 is independently:

- 1) hydrogen,
 2) $-\text{C}_1\text{-C}_{10}$ alkyl,
 3) $-\text{C}_2\text{-C}_8$ alkenyl,
 4) $-(\text{CH}_2)_{\text{n}}\text{OR}^{\text{e}}$,
 5) $-\text{S}(\text{O})_{\text{m}}\text{R}^{\text{e}}$,
 6) $-\text{S}(\text{O})_{\text{m}}\text{NR}^{\text{c}}\text{R}^{\text{d}}$,
 7) $-(\text{CH}_2)_{\text{n}}\text{NR}^{\text{c}}\text{R}^{\text{d}}$,

- 8) $-\text{OC}(\text{O})\text{R}^{\text{e}}$,
 9) $-\text{C}(\text{O})\text{OR}^{\text{e}}$,
 10) $-\text{CN}$,
 11) $-\text{C}(\text{O})\text{NR}^{\text{c}}\text{R}^{\text{d}}$,
 12) $-\text{NR}^{\text{c}}\text{C}(\text{O})\text{R}^{\text{e}}$,
 13) $-\text{NR}^{\text{c}}\text{C}(\text{O})\text{OR}^{\text{e}}$,
 14) $-\text{NR}^{\text{c}}\text{C}(\text{O})\text{NR}^{\text{c}}\text{R}^{\text{d}}$,
 15) $-\text{NR}^{\text{c}}\text{S}(\text{O})_{\text{m}}\text{R}^{\text{e}}$,
 16) $=\text{NR}^{\text{f}}$,
 17) $-\text{C}_3\text{-C}_7$ cycloalkyl,
 18) $-\text{O-C}_3\text{-C}_6$ cycloalkyl,
 19) $-\text{C}_1\text{-C}_{10}$ alkylene- $\text{C}_3\text{-C}_6$ cycloalkyl,
 20) $-\text{O-C}_1\text{-C}_{10}$ alkylene- $\text{C}_3\text{-C}_6$ cycloalkyl,
 21) HetB,
 22) $-\text{O-HetB}$,
 23) $-\text{C}_1\text{-C}_{10}$ alkylene-HetB,
 24) $-\text{O-C}_1\text{-C}_{10}$ alkylene-HetB,
 25) AryB,
 26) $-\text{O-AryB}$,
 27) $-\text{C}_1\text{-C}_{10}$ alkylene-AryB, or
 28) $-\text{O-C}_1\text{-C}_{10}$ alkylene-AryB,
- wherein R^4 is unsubstituted or substituted with one to four R^6 ;

AryB is a 5- to 6-membered monocyclic aromatic ring with 0, 1, 2, or 3 ring atoms independently selected from N, O and S, unsubstituted or substituted with one to four R^{e} ;

HetB is a 4- to 7-membered saturated or monounsaturated monocyclic ring with 1, 2, or 3 heteroatom ring atoms independently selected from N, N as a quaternary salt, O and S, unsubstituted or substituted with one to three R^{a} ;

30

R^5 is

- 1) hydrogen,
 2) $\text{C}_1\text{-C}_{10}$ alkyl,
 3) $-\text{C}_2\text{-C}_8$ alkenyl,
 4) $-(\text{CH}_2)_{\text{u}}\text{OR}^{\text{e}}$,
 5) $-\text{S}(\text{O})_{\text{v}}\text{R}^{\text{e}}$,
 6) $-\text{S}(\text{O})_{\text{v}}\text{NR}^{\text{c}}\text{R}^{\text{d}}$,

35

- 7) $-(\text{CH}_2)_u\text{NR}^c\text{R}^d$,
 8) $-\text{OC}(\text{O})\text{R}^e$,
 9) $-\text{C}(\text{O})\text{OR}^e$,
 10) $-\text{CN}$,
 5 11) $-\text{C}(\text{O})\text{NR}^c\text{R}^d$,
 12) $-\text{NR}^c\text{C}(\text{O})\text{R}^e$,
 13) $-\text{NR}^c\text{C}(\text{O})\text{OR}^e$,
 14) $-\text{NR}^c\text{C}(\text{O})\text{NR}^c\text{R}^d$,
 15) $-\text{NR}^c\text{S}(\text{O})_v\text{R}^e$,
 10 16) $=\text{NR}^{11}$,
 17) $-\text{C}_3\text{-C}_7$ cycloalkyl,
 18) $-\text{O-C}_3\text{-C}_6$ cycloalkyl,
 19) $-\text{C}_1\text{-C}_{10}$ alkylene- $\text{C}_3\text{-C}_6$ cycloalkyl,
 20) $-\text{O-C}_1\text{-C}_{10}$ alkylene- $\text{C}_3\text{-C}_6$ cycloalkyl,
 15 21) HetB,
 22) $-\text{O-HetB}$,
 23) $-\text{C}_1\text{-C}_{10}$ alkylene-HetB,
 24) $-\text{O-C}_1\text{-C}_{10}$ alkylene-HetB,
 25) AryB,
 20 26) $-\text{O-AryB}$,
 27) $-\text{C}_1\text{-C}_{10}$ alkylene-AryB, or
 28) $-\text{O-C}_1\text{-C}_{10}$ alkylene-AryB,

wherein R^5 is unsubstituted or substituted with one to four R^6 ;

25 each occurrence of R^6 is independently:

- 1) halogen,
 2) $-\text{C}_1\text{-C}_6$ alkyl,
 3) $-\text{OR}^e$,
 4) $-\text{S}(\text{O})_v\text{R}^e$,
 30 5) $-\text{S}(\text{O})_v\text{NR}^c\text{R}^d$,
 6) $-\text{C}(\text{O})\text{R}^e$,
 7) $-\text{OC}(\text{O})\text{R}^e$,
 8) $-\text{C}(\text{O})\text{OR}^e$,
 9) $-\text{CN}$,
 35 10) $-\text{C}(\text{O})\text{NR}^c\text{R}^d$,
 11) $-\text{C}(\text{NH})\text{NR}^c\text{R}^d$,
 12) $-(\text{CH}_2)_u\text{NR}^c\text{R}^d$,

- 13) $-(CH_2)_uNR^cR^d$,
 14) $-N(R^c)(C(O)R^c)$,
 15) $-N(R^c)(C(O)OR^c)$,
 16) $-N(R^c)(C(O)NR^cR^d)$,
 5 17) $-N(R^c)(S(O)_vR^c)$, or
 18) HetB;

R^7 is

- 1) hydrogen,
 10 2) C_1 - C_3 alkyl, or
 3) C_3 - C_7 cycloalkyl,

wherein C_1 - C_3 alkyl and C_3 - C_7 cycloalkyl are unsubstituted or substituted with one to three R^a ,

15 R^8 is

- 1) hydrogen,
 2) C_1 - C_4 alkyl, or
 3) C_3 - C_7 cycloalkyl;

20 R^9 is

- 1) hydrogen,
 2) C_1 - C_4 alkyl, or
 3) C_3 - C_7 cycloalkyl;

25 R^{10} is

- 1) hydrogen,
 2) C_1 - C_4 alkyl, or
 3) C_3 - C_7 cycloalkyl;

30 R^{11} is

- 1) hydrogen,
 2) C_1 - C_4 alkyl, or
 3) C_3 - C_7 cycloalkyl;

35 R^{12} and R^{13} are independently:

- 1) hydrogen,
 2) $-SC_1$ - C_3 alkyl,

- 3) C₁-C₃ alkyl,
- 4) -(C₁-C₃alkylene)_nOC₁-C₃alkyl, or
- 5) -(C₁-C₃alkylene)_nNC₁-C₃alkyl,

wherein -SC₁-C₃alkyl, C₁-C₃ alkyl, -(C₁-C₃alkylene)_nOC₁-C₃alkyl and -(C₁-
 5 C₃alkylene)_nNC₁-C₃alkyl are unsubstituted or substituted with one to seven fluorines, or,
 alternatively, R¹² and R¹³ together with the carbon to which they are attached, form a
 monocyclic C₄-C₇ cycloalkyl or a monocyclic C₄-C₇ heterocycloalkyl with 1, 2, or 3
 heteroatom ring atoms independently selected from N, O and S, wherein C₄-C₇ cycloalkyl
 and C₄-C₇ heterocycloalkyl are unsubstituted or substituted with one to three substituents
 10 independently selected from -F, -OH and -OC₁-C₃alkyl;

R¹⁴ is

- 1) hydrogen,
- 2) C₁-C₄ alkyl, or
- 15 3) C₃-C₇ cycloalkyl;

each occurrence of R^a is independently:

- 1) hydrogen,
- 2) halogen,
- 20 3) C₁-C₃alkyl,
- 4) -NR^cR^d, or
- 5) -OR^e;

each occurrence of R^b is independently:

- 25 1) hydrogen,
- 2) -C₁-C₆ alkyl,
- 3) -OC₁-C₆ alkyl,
- 4) OH,
- 5) N(R⁹)₂, or
- 30 6) halogen,

wherein -C₁-C₃ alkyl is unsubstituted or substituted with one to three R^a;

each occurrence of R^c and R^d is independently:

- 1) hydrogen,
- 35 2) -C₁-C₁₀ alkyl,
- 3) -C₂-C₁₀ alkenyl,
- 4) -C₃-C₆ cycloalkyl,

- 5) -C₁-C₁₀ alkylene-C₃-C₆ cycloalkyl,
- 6) HetA,
- 7) -C₁-C₁₀alkylene-HetB,
- 8) AryB,
- 5 9) -C₁-C₁₀ alkylene-AryB, or
- 10) -C₁-C₁₀ alkylene-HetB,

or, alternatively, R^c and R^d together with the nitrogen atom to which they are attached, form a 4- to 7-membered heterocycloalkyl optionally containing one to two additional heteroatoms independently selected from O, S and -NR^g, and wherein each R^c and R^d is unsubstituted or substituted with one to three R^f;

each occurrence of R^e is independently:

- 1) hydrogen,
- 2) -C₁-C₁₀alkyl,
- 15 3) -C₂-C₁₀ alkenyl,
- 4) -OH,
- 5) -OC₁-C₄ alkyl,
- 6) -C₃-C₆ cycloalkyl,
- 7) -C₁-C₁₀ alkylene-C₃-C₆ cycloalkyl,
- 20 8) HetB,
- 9) -C₁-C₁₀ alkylene-HetB,
- 10) AryB,
- 11) -C₁-C₁₀ alkylene-AryB,
- 12) -C₁-C₁₀ alkylene-HetB, or
- 25 13) halogen,

wherein each R^e is unsubstituted or substituted with one to three R^h,

each occurrence of R^f is independently:

- 1) halogen,
- 30 2) -C₁-C₁₀ alkyl,
- 3) -OH,
- 4) -OC₁-C₄ alkyl,
- 5) -S(O)_mC₁-C₄ alkyl,
- 6) -CN,
- 35 7) -CF₃,
- 8) -OCHF₂,
- 9) -OCF₃, or

10) NH_2 ,

wherein $-\text{C}_1\text{-C}_{10}$ alkyl is unsubstituted or substituted with one to three substituents independently selected from $-\text{OH}$, halogen, cyano, and $-\text{S}(\text{O})_2\text{CH}_3$;

5 each occurrence of R^g is independently:

- 1) hydrogen,
- 2) $-\text{C}(\text{O})\text{R}^e$, or
- 3) $-\text{C}_1\text{-C}_{10}$ alkyl,

wherein $-\text{C}_1\text{-C}_{10}$ alkyl is unsubstituted or substituted with one to five fluorines;

10

each occurrence of R^h is independently:

- 1) halogen,
- 2) $-\text{C}_1\text{-C}_{10}$ alkyl,
- 3) $-\text{OH}$,
- 4) $-\text{OC}_1\text{-C}_4$ alkyl,
- 5) $-\text{S}(\text{O})_m\text{C}_1\text{-C}_4$ alkyl,
- 6) $-\text{CN}$,
- 7) $-\text{CF}_3$,
- 8) $-\text{OCHF}_2$, or
- 9) $-\text{OCF}_3$,

15

20

wherein $-\text{C}_1\text{-C}_{10}$ alkyl is unsubstituted or substituted with one to three substituents independently selected from: $-\text{OH}$, halogen, cyano, or $-\text{S}(\text{O})_2\text{CH}_3$;

each occurrence of R^i is independently:

- 1) $-\text{C}_1\text{-C}_8$ alkyl,
- 2) $-\text{C}_2\text{-C}_8$ alkenyl,
- 3) $-\text{C}_2\text{-C}_8$ alkynyl,
- 4) halogen,
- 5) $-\text{OR}^e$,
- 6) $-\text{S}(\text{O})_m\text{R}^e$,
- 7) $-\text{S}(\text{O})_m\text{NR}^c\text{R}^d$,
- 8) $-\text{C}(\text{O})\text{R}^e$,
- 9) $-\text{OC}(\text{O})\text{R}^e$,
- 10) $-\text{C}(\text{O})\text{OR}^e$,
- 11) $-\text{CN}$,
- 12) $-\text{C}(\text{O})\text{NR}^c\text{R}^d$,
- 13) $-\text{NR}^c\text{R}^d$,

25

30

35

- 14) $-(\text{CH}_2)_n\text{NR}^c\text{R}^d$,
 15) $-\text{NR}^c\text{C}(\text{O})\text{R}^e$,
 16) $-\text{NR}^c\text{C}(\text{O})\text{OR}^e$,
 17) $-\text{NR}^c\text{C}(\text{O})\text{NR}^c\text{R}^d$,
 5 18) $-\text{NR}^c\text{S}(\text{O})_m\text{R}^e$,
 19) $=\text{NH}$,
 20) $-\text{CF}_3$,
 21) $-\text{OCF}_3$, or
 22) $-\text{OCHF}_2$;

10

each occurrence of R^j is independently:

- 1) hydrogen,
 2) $\text{C}_1\text{-C}_3$ alkyl,
 3) OR^{10} ,
 15 4) $=\text{NR}^{10}$,
 5) $\text{N}(\text{R}^{10})_2$, or
 6) halogen,

wherein $\text{C}_1\text{-C}_3$ alkyl unsubstituted or substituted with one to three R^b ;

- 20 each n is independently 0, 1, 2, 3, 4, 5 or 6;
 each m is independently 0, 1 or 2;
 each p is independently 1 or 2;
 each q is independently 0, 1, 2, 3, 4, 5 or 6;
 each s is independently 0, 1, 2 or 3;
 25 each t is independently 0, 1, 2 or 3;
 each u is independently 0, 1, 2, 3, 4, 5 or 6; and
 each v is independently 0, 1, or 2.

2. A compound of Claim 1 wherein
 30 T, U and V are each CH;
 or a pharmaceutically acceptable salt thereof.

3. The compound of Claim 1 wherein
 W is O;
 35 or a pharmaceutically acceptable salt thereof.

4. The compound of Claim 1 wherein
Q is CR³; and
R³ is hydrogen;
or a pharmaceutically acceptable salt thereof.
- 5
5. The compound of Claim 1 wherein
X is CH₂;
or a pharmaceutically acceptable salt thereof.
- 10
6. The compound of Claim 5 wherein
Y is O or CH₂; and
Z is O or CH₂;
or a pharmaceutically acceptable salt thereof.
- 15
7. The compound of Claim 1 wherein
Y is CH₂; and
Z is O;
or a pharmaceutically acceptable salt thereof.
- 20
8. The compound of Claim 1 wherein R¹ and R² are independently selected
from:
1) hydrogen,
2) -C₁-C₈ alkyl, and
3) -C(O)OR^e,
25 wherein -C₁-C₈ alkyl is unsubstituted or substituted with one to three R^a,
provided that if R¹ is -C(O)OR^e, then R² is not -C(O)OR^e;
or a pharmaceutically acceptable salt thereof.
- 30
9. The compound of Claim 1 wherein
R¹ and R² are independently selected from
1) -C₁-C₈ alkyl, and
2) -C(O)OR^e,

provided if R^1 is $-C(O)OR^e$, then R^2 is $-C_1-C_8$ alkyl, and if R^2 is $-C(O)OR^e$, then R^1 is $-C_1-C_8$ alkyl; or a pharmaceutically acceptable salt thereof.

10. The compound of Claim 1 wherein
5 R^{12} and R^{13} are independently C_1-C_3 alkyl, wherein C_1-C_3 alkyl is unsubstituted or substituted with one to seven fluorines,
or alternatively R^{12} and R^{13} together with the carbon to which they are attached form a monocyclic C_4-C_6 cycloalkyl unsubstituted or substituted with one to three substituents independently selected from $-F$, $-OH$ and $-OC_1-C_3$ alkyl;
10 or a pharmaceutically acceptable salt thereof.

11. The compound of Claim 1 wherein
A is
1) $-C(=NH)-NH$,
15 2) AryC, or
3) HetC,
wherein A is unsubstituted or substituted with one to four R^i ;
or a pharmaceutically acceptable salt thereof.

20 12. The compound of Claim 1 wherein
A is
1) AryC, or
2) HetC,
wherein A is unsubstituted or substituted with one to four R^i ;
25 or a pharmaceutically acceptable salt thereof.

13. The compound of Claim 1 wherein
L is
1) absent, or
30 2) R^4 ,
wherein L is unsubstituted or substituted with 1-4 substituents selected from R^e ; and
each occurrence of R^4 is independently:
1) hydrogen,

- 2) $-C_1-C_{10}$ alkyl,
- 3) $-(CH_2)_nOR^e$,
- 4) $-(CH_2)_nNR^cR^d$, or
- 5) $-C_1-C_{10}$ alkylene-HetB,

5 wherein R^4 is unsubstituted or substituted with one to four R^6 ;
or a pharmaceutically acceptable salt thereof.

14. The compound of Claim 13 wherein
each occurrence of R^4 is independently:

- 10 1) $-C_1-C_{10}$ alkyl,
- 2) $-(CH_2)_nNR^cR^d$, or
- 3) $-C_1-C_{10}$ alkylene-HetB,

wherein R^4 is unsubstituted or substituted with one to four R^6 ;
or a pharmaceutically acceptable salt thereof.

15

15. The compound of Claim 1 wherein
M is

- 1) R^5 , or
- 2) $-NHR^5$,

20 wherein M is unsubstituted or substituted with 1 – 4 substituents selected from R^6 ; and

R^5 is

- 1) hydrogen,
- 2) C_1-C_6 alkyl,
- 25 3) $-C_1-C_4$ alkyl- $(NR^cR^d)_2$,
- 4) $-(CH_2)_nNR^cR^d$, or
- 5) $-C_1-C_{10}$ alkylene-HetB,

wherein R^5 is unsubstituted or substituted with one to four R^6 ;
or a pharmaceutically acceptable salt thereof.

30

16. The compound of Claim 15 wherein
 R^5 is

- 1) $-C_1-C_4$ alkyl- $(NR^cR^d)_2$, or
- 2) $-(CH_2)_nNR^cR^d$,

35 wherein R^5 is unsubstituted or substituted with one to four R^6 ;
or a pharmaceutically acceptable salt thereof.

17. The compound of Claim 1 wherein
T, U and V are CH;

W is O;

Q is CR³;

5 X is CH₂;

Y is O or CH₂;

Z is O or CH₂;

R¹ and R² are independently selected from:

- 10 1) hydrogen,
 2) -C₁-C₈ alkyl, and
 3) -C(O)OR^e,

wherein -C₁-C₈ alkyl is unsubstituted or substituted with one to three R^a, provided that if R¹
is -C(O)OR^e, then R² is independently selected from hydrogen and -C₁-C₈ alkyl;

15

R³ is hydrogen;

R¹² and R¹³ are independently C₁-C₃ alkyl, wherein C₁-C₃ alkyl is unsubstituted or
substituted with one to seven fluorines,

20 or alternatively R¹² and R¹³ together with the carbon to which they are attached form a
monocyclic C₄-C₆ cycloalkyl unsubstituted or substituted with one to three substituents
independently selected from -F, -OH and -OC₁-C₃alkyl;

A is

- 25 1) -C(=NH)-NH,
 2) AryC, or
 3) HetC,

wherein A is unsubstituted or substituted with one to four Rⁱ;

30 L is

- 1) absent, or
 2) R⁴,

wherein L is unsubstituted or substituted with 1-4 substituents selected from R^e;

each occurrence of R^4 is independently:

- 1) hydrogen,
- 2) $-C_1-C_{10}$ alkyl,
- 3) $-(CH_2)_nOR^e$,
- 5 4) $-(CH_2)_nNR^cR^d$, or
- 5) $-C_1-C_{10}$ alkylene-HetB,

wherein R^4 is unsubstituted or substituted with one to four R^6 ;

M is

- 1) R^5 , or
- 10 2) $-NHR^5$,

wherein M is unsubstituted or substituted with 1 – 4 substituents selected from R^6 ; and

R^5 is

- 1) hydrogen,
- 15 2) $-C_1-C_6$ alkyl,
- 3) $-C_1-C_4$ alkyl- $(NR^cR^d)_2$,
- 4) $-(CH_2)_nNR^cR^d$, or
- 5) $-C_1-C_{10}$ alkylene-HetB,

wherein R^5 is unsubstituted or substituted with one to four R^6 ;

20 or a pharmaceutically acceptable salt thereof.

18. The compound of Claim 1 wherein

T, U and V are CH;

25 W is O;

Q is CR^3 ;

R^3 is hydrogen;

X is CH_2 ;

30 Y is CH_2 ;

Z is O;

R^1 and R^2 are independently selected from

- 1) $-C_1-C_6$ alkyl, and
- 35 2) $-C(O)OR^e$,

wherein -C₁-C₆ alkyl is unsubstituted or substituted with one to three R^a, provided that if R¹ is -C(O)OR^e, then R² is -C₁-C₆ alkyl;

5 R¹² and R¹³ are independently C₁-C₃ alkyl, wherein C₁-C₃ alkyl is unsubstituted or substituted with one to seven fluorines;

A is

- 1) AryC, or
- 2) HetC,

10 wherein A is unsubstituted or substituted with one to four Rⁱ;

L is

- 1) absent, or
- 2) R⁴,

15 wherein L is unsubstituted or substituted with 1-4 substituents selected from R^e;

each occurrence of R⁴ is independently:

- 1) -C₁-C₁₀ alkyl,
- 2) -(CH₂)_nNR^cR^d, or
- 3) -C₁-C₁₀alkylene-HetB,

20 wherein R⁴ is unsubstituted or substituted with one to four R⁶;

M is

- 1) R⁵, or
- 2) -NHR⁵,

25 wherein M is unsubstituted or substituted with 1 – 4 substituents selected from R⁶;

R⁵ is


- 1) -C₁-C₄alkyl-(NR^cR^d)₂, or
- 2) -(CH₂)_nNR^cR^d,

30 wherein R⁵ is unsubstituted or substituted with one to four R⁶;


or a pharmaceutically acceptable salt thereof.

19. The compound of Claim 1 which is selected from:


35




,




,



,




,




5


,




,



,




,



or a pharmaceutically acceptable salt thereof.


20. The compound of Claim 1 which is:



5

or a pharmaceutically acceptable salt thereof.


21. The compound of Claim 1 which is:



10


or a pharmaceutically acceptable salt thereof.

22. The compound of Claim 1 which is:



or a pharmaceutically acceptable salt thereof.

23. The compound of Claim 1 which is:



or a pharmaceutically acceptable salt thereof.

24. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of Claims 1 to 23, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

25. A pharmaceutical composition according to Claim 24, which further comprises a therapeutically effective amount of a beta-lactamase inhibitor compound.

26. A pharmaceutical composition according to Claim 25, wherein the beta-lactamase inhibitor compound is selected from the group consisting of relebactam, tazobactam, clavulanic acid, sulbactam, and avibactam.

27. A method for treating a bacterial infection which comprises administering to a subject in need of such treatment (i) a therapeutically effective amount of a compound according to any one of Claims 1 to 23, or a pharmaceutically acceptable salt thereof, optionally in combination with a beta-lactamase inhibitor compound or (ii) a pharmaceutical composition according to any one of claims 24 to 26.

28. Use of a compound according to any one of Claims 1 to 23, or a pharmaceutically acceptable salt thereof, for treating a bacterial infection, in the manufacture of a medicament for treating a bacterial infection, in combination with a beta-lactamase inhibitor compound for treating a bacterial infection, or in combination with a beta-lactamase inhibitor compound in the manufacture of a medicament for treating a bacterial infection.

29. The method of Claim 27 or the use of claim 28, wherein the beta-lactamase inhibitor compound is selected from the group consisting of relebactam, tazobactam, clavulanic acid, sulbactam, and avibactam.

30. The method of claim 27 or 29 or the use of claim 28, wherein the bacterial infection is due to *Pseudomonas* spp., *Klebsiella* spp., *Enterobacter* spp., *Escherichia* spp., *Morganella* spp., *Citrobacter* spp., *Serratia* spp. or *Acinetobacter* spp.